Jiangsu Chiatai Qingjiang Pharmaceutical Co., Ltd.

To evaluate the effect of food on the pharmacokinetics (PK) of QJ-19-0002 after a single oral administration of QJ-19-0002 tablets in healthy subjects

Main research purpose: The cefaclor dry suspension (specification: 0.125g) developed by Jiangsu Zhengda Qingjiang Pharmaceutical Co., Ltd. was used as the test preparation. According to the relevant provisions of bioequivalence studies, the relative bioavailability of the two preparations in healthy humans was compared with that of the cefaclor dry suspension (trade name: Xikeluo®, reference preparation, specification: 0.125g) produced by Suzhou Xikro Pharmaceutical Co., Ltd. to investigate the human bioequivalence of the two preparations. Secondary research purpose: Compare the safety of the cefaclor dry suspension test preparation (specification: 0.125g) and the reference preparation (specification: 0.125g) in healthy trial participants.

Main purpose: Using pharmacokinetic parameters as the primary endpoint evaluation indicators, the pharmacokinetic behavior of the test preparation risedronate sodium tablets (manufacturer: Jiangsu Zhengda Qingjiang Pharmaceutical Co., Ltd.) and the reference preparation risedronate sodium tablets (licensed manufacturer: Allergan Pharmaceuticals International Limited, trade name: ACTONEL®) in healthy subjects after oral administration under fasting state was compared to evaluate the bioequivalence of the two preparations. Secondary purpose: Observe the safety of the test preparation risedronate sodium tablets and the reference preparation risedronate sodium tablets in healthy subjects.